Why shares of Novavax crashed 37.7% in May

Delays frustrated investors.

| More on:
disappointed and sad woman

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of coronavirus vaccine maker Novavax (NASDAQ: NVAX) tanked by 37.7% in May, according to data provided by S&P Global Market Intelligence. The collapse was a result of the company's repeated delays with the manufacturing of its coronavirus vaccine as well as its announcement that it won't file for the candidate's regulatory approval before the third quarter.

So what

The combination of delays with regulatory filings and manufacturing delays means that Novavax won't be able to deliver its contractually obligated doses to the European Union before 2022. In short, certain raw materials needed for the vaccine are in scant supply. Furthermore, the company will be even further behind other vaccine makers like Pfizer and Moderna, which are already on the market and in wide distribution.

In the long run, however, these issues probably won't harm the company's revenue making potential. Even amid the delays, Novavax is still signing new sales agreements with groups like the Gavi Vaccine Alliance, which agreed to buy 350 million doses of its vaccine on May 6. Likewise, Novavax still has commitments to make more than 1.1 billion doses in conjunction with its manufacturing collaborators. So, while May's losses might be frustrating, they probably don't reflect much genuine destruction of shareholder value. It's likely that the stock will rebound once sales revenue starts to be reflected in earnings reports.

Now what

While investors are unlikely to have much patience for further delays, Novavax is still proceeding with its plans to commercialize its coronavirus vaccine globally, and it will almost certainly continue to succeed in doing so. Notably, in early May it also reported that its candidate is effective against at least one viral variant, which should keep it competitive with the currently marketed vaccines. But shareholders will need to wait a bit longer before the full impact of the revenue is reflected in the company's quarterly earnings reports.

Beyond that, the company is also pursuing its combination vaccine project, which could inoculate people against both influenza and the coronavirus in a single jab. On May 10, it published preliminary evidence from preclinical studies that suggests the combination vaccine could be effective.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Woman in business suit holds both hands out with a question mark above each hand.
International Stock News

Better core AI stock: Nvidia or Palantir Technologies?

Which of these top innovation stocks is the better buy as a core AI holding?

Read more »

A Tesla car driving along a road at sunset.
International Stock News

Prediction: This artificial intelligence (AI) stock could be the biggest winner of the second half of 2025

Let's take a look.

Read more »

Digital rocket on a laptop.
International Stock News

Prediction: After losing more than $1 trillion in market cap earlier this year, this monster artificial intelligence (AI) stock will become the most valuable business in the world by the end of the year

I'll explain why investor enthusiasm is on the rise and detail why I think the stock is poised for an…

Read more »

A tech worker wearing a mask holds a computer chip.
International Stock News

Think it's too late to buy Nvidia stock? Here's the biggest reason why there's still time.

This is just the beginning for AI, and Nvidia is well-positioned to tap into that high growth.

Read more »

Happy man working on his laptop.
International Stock News

Meta Platforms stock will soar over the next 5 years. Here's 1 reason why.

Over the last five years, Meta Platforms stock has been one of the best names to own.

Read more »

Amazon boxes stacked up on a doorstep.
International Stock News

Prediction: This artificial intelligence (AI) stock could be the surprise winner of 2025

The business is strong on many fronts.

Read more »

Hand with AI in capital letters and AI-related digital icons.
International Stock News

Should you forget Nvidia and buy this artificial intelligence (AI) stock right now?

Let's take a closer look.

Read more »

A man looking at his laptop and thinking.
International Stock News

Should you buy Nvidia while it's below $150?

Let's take a look.

Read more »